Late last year, The Jewish Hospital-Mercy Health in Cincinnati received a first-place award in a multi-state competition for its efforts to reduce Clostridium difficile infections among inpatients.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min C. diff is the leading cause of ...

New live bacterial product for stubborn superbug improves quality of life Microbiome therapeutic tackles C. diff, the most common health care-associated infectious agent in the US. Date: January 31, ...

Bethesda, MD (Feb. 21, 2024) — In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological ...

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

The pathogen C. diff—the most common cause of health care-associated infectious diarrhea—can use a compound that kills the human gut's resident microbes to survive and grow, giving it a competitive ...